Enzon retains marketed products, rights to certain royalty streams, and a production plant, while the new firm will utilize PEG and LNA technologies.

Enzon Pharmaceuticals decided to spin off its biotechnology segment while Enzon will focus on its specialty pharma franchise. The new entity will be receive $150 million in cash.

Each company will operate with independent management teams. Following the spin-off, Enzon will retain marketed products Abelcet® for fungal infections, Adagen® for severe combined immunodeficiency disease, DepoCyt® for lymphomatous meningitis, and Oncaspar® for acute lymphoblastic leukemia. The company will also retain rights to current PEG-related royalties including those from PEG-Intron® for hepatitis C, Cimzia® in development for rheumatoid arthritis and Crohn’s disease, and Hematide®, which is an erythropoiesis-stimulating agent in development. Finally, Enzon will also gain rights to the manufacturing facility in Indianapolis.

Seed money for the biotechnology firm is expected to carry the company forward for two to three years. It will leverage its customized PEGylation technology for licensing, collaborations, and future royalty generation. It will also take with it the locked nucleic acid (LNA) technology to aid in oncology R&D.

Previous articleInvestigators Identify Peptides Involved in Cognitive Deficits in Alzheimer’s
Next articleAgilent Ups Therapeutic Nucleic Acids Manufacturing Capacity